Failed early

relapsing MS · Interferon beta

Controlled phase 2 trials were negative.

Trials
10
Running now
1
Controlled phase 2/3 trials
2
People in controlled trials
267

Deciding trials (phase 2): 0 met, 1 did not.

Other linked trials: 9

Dose comparisons, trials against another medicine, add-on trials, phase 1 and uncontrolled studies. They are listed below but do not set the status.

Trials

  • INCREASEdecides the statusStopped, other reason

    Phase 2 · 2018 · Placebo-controlled · MSFT-NCT03387046

  • SOLARdecides the statusMissed main goal

    Phase 2 · 2011 · Placebo-controlled · MSFT-NCT01285401

    At 48 weeks, 36.3% of patients who received high-dose vitamin D 3 had NEDA-3, without a statistically significant difference in NEDA-3 status between groups (placebo 35.3%; odds ratio 0.93; 95% confidence interval [CI] 0.53-1.63; p = 0.80).

    Read by software from the paper's abstract

Other linked trials: 9

These linked trials do not set the status.

The deciding phase and counts come from the Trial Bank’s fixed rules.

Lab evidence

Lab studies in animals or cells. Results in animals often do not hold in people, and these studies never change the status of an idea.

Loading lab studies…

Loading reviews and guidelines…

History

  • 2026-10-28Status changed from Being tested to Failed early
  • 2026-10-27First listed as Being tested

Related hypotheses

Assembled by software from public sources and not checked by people. Each record links to its source. Report an error